Biomarkers: The next generation

Nature Reviews Drug Discovery

Volumn 9, Issue 6, 2010, Pages 415-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DEATH; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HEART INFARCTION; HUMAN; MEDICAL DECISION MAKING; NEPHROTOXICITY; PRIORITY JOURNAL; STROKE;

EID: 77953159200     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3196     Document Type: Editorial

References (3)

1. Lanone, P. Natixis Securities analyst report. (May 2009)
2. Tobert, J. A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nature Rev. Drug Discov. 2, 517-526 (2003)
3. Institute of Medicine. Evaluation of biomarkers and surrogate endpoints in chronic disease. IOM website [online], http://www.iom.edu/Reports/ 2010Evaluation-of-Biomarkers-and-Surrogate-Endpoints-in-Chronic-Disease.aspx (2010).